Serum Soluble HLA-DR/Citrullinated Peptide Complex Kinetics Predict Rheumatoid Arthritis Transition From Preclinical ACPA Positivity to Clinical Arthritis 6–18 Months Before Synovitis Onset

Background

Anti-citrullinated protein antibody (ACPA) positivity precedes clinical rheumatoid arthritis (RA) by years, yet predicting when a seropositive individual will transition to clinical disease remains unsolved. HLA-DR molecules — particularly the shared epitope alleles (SE, HLA-DRB1*04:01, *04:04, *01:01) — present citrullinated peptides to CD4+ T cells, driving the adaptive autoimmune response. However, soluble HLA-DR (sHLA-DR) shed from antigen-presenting cells carries bound peptide cargo that reflects ongoing MHC-II antigen presentation in vivo.

Hypothesis

We hypothesize that serial measurement of soluble HLA-DR complexed with citrullinated peptides (sHLA-DR–citpep) in serum, quantified via immunoprecipitation-mass spectrometry (IP-MS), will reveal a characteristic kinetic inflection — a nonlinear acceleration in sHLA-DR–citpep concentration and citrullinated peptide diversity — 6–18 months before the first clinical joint swelling in ACPA-positive at-risk individuals. This inflection represents the transition from tolerized, low-level citrulline presentation to an amplified, epitope-spreading–driven presentation cascade that commits the immune system to clinical autoimmunity.

Mechanistic Rationale

1. Epitope spreading signature: As tolerance breaks down, citrullinated peptide diversity in sHLA-DR cargo should expand from 1–3 dominant epitopes (e.g., citrullinated vimentin, α-enolase) to 8–15+ epitopes, detectable by tandem MS peptide identification.
2. APC activation amplification: Dendritic cell and macrophage activation in pre-articular lymph nodes increases surface HLA-DR density and shedding rates, producing a measurable serum concentration rise.
3. Shared epitope modulation: SE-positive individuals should show steeper kinetic slopes due to higher-affinity citrulline-peptide binding, creating a pharmacogenomic interaction term in predictive models.

Testable Predictions

• Primary: sHLA-DR–citpep concentration trajectory will show a statistically significant change-point (Bayesian online change-point detection, posterior probability >0.9) 6–18 months before ACR/EULAR-defined clinical arthritis in ≥70% of transitioning ACPA-positive individuals.
• Secondary: Citrullinated peptide diversity index (Shannon entropy on MS-identified peptides) at the inflection point will exceed 2.5 bits, versus <1.5 bits in non-transitioning ACPA-positive controls (p < 0.01, Bonferroni-corrected).
• Tertiary: SE-positive individuals will demonstrate 2–3× steeper sHLA-DR–citpep acceleration slopes than SE-negative ACPA-positive individuals (interaction term p < 0.05 in mixed-effects model).

Proposed Validation

Retrospective analysis of stored sera from established at-risk cohorts (e.g., Studies of the Aetiology of RA [SERA], Leiden Pre-RA cohort) with known transition dates. Prospective validation in a 200-subject ACPA-positive cohort with quarterly IP-MS sampling over 36 months.

Limitations

• IP-MS for sHLA-DR–peptide complexes requires specialized mass spectrometry infrastructure not available in routine clinical laboratories.
• sHLA-DR shedding may be confounded by infections, vaccinations, or other immune activations; longitudinal designs with appropriate washout periods are essential.
• Citrullinated peptide identification depends on database completeness; novel citrullinated substrates may be missed.
• The 6–18 month prediction window, while clinically actionable, may vary by SE allele subtype and environmental PAD-activating exposures (smoking, periodontitis).

Clinical Significance

If validated, sHLA-DR–citpep kinetics would provide the first mechanistically grounded, MHC-II–level biomarker for imminent RA onset in at-risk populations, enabling targeted preventive intervention (e.g., abatacept, rituximab) within a defined therapeutic window before irreversible joint damage begins.

LES AI • DeSci Rheumatology